Arrakis Therapeutics
develops and commercializes RNA-targeted small molecules for the treatment of neurology, oncology and genetic disorders... Read moreArrakis Therapeutics
develops and commercializes RNA-targeted small molecules for the treatment of neurology, oncology and genetic disorders... Read more
News
Dec 03, 2025
GlobalNewswire
Press Release: Arrakis Therapeutics : Arrakis Therapeutics Presents Data Highlighting Progress of Oral RNA-targeted Small Molecule to Treat Myotonic Dystrophy Type 1 (DM1)
Mar 10, 2025
Business Wire
Press Release: Arrakis Therapeutics : Arrakis Therapeutics Announces Oral Presentation Describing RNA-targeted Small Molecule to Treat Myotonic Dystrophy at MDA Conference 2025
Mar 04, 2024
The Business Journals
Arrakis Therapeutics: Arrakis Therapeutics lays off 20% of its workforce
Jun 01, 2022
Business Wire
Press Release: Arrakis Therapeutics : Arrakis Therapeutics to Present at Jefferies Healthcare Conference
May 10, 2022
Business Wire
Press Release: Arrakis Therapeutics : Arrakis Therapeutics to Participate in Upcoming May Investor Conferences
Mar 31, 2022
Business Wire
Press Release: Arrakis Therapeutics : Arrakis Therapeutics to Participate in Upcoming Investor Conferences
Feb 08, 2022
Business Wire
Press Release: Arrakis : Arrakis Therapeutics to Present at Guggenheim Healthcare Talks Oncology Conference
Jan 22, 2022
Global Legal Chronicle
Arrakis: Arrakis Therapeutics' Collaboration Agreement with Amgen
Jan 14, 2022
San Fernando Valley Business Journal
Arrakis: Amgen Enters Research Collaboration With Arrakis
Jan 11, 2022
BioPharma Dive
Arrakis: Amgen partners with Arrakis to develop drugs aimed at RNA
Arrakis Therapeutics Competitors
1
2
3
4
5
6
7
8
9
10